Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024

Rhea-AI Summary

Enanta Pharmaceuticals announced that data from the SPRINT study of EDP-235 has been accepted for presentation at ESCMID Global 2024. The study focused on the efficacy and safety of EDP-235 in non-hospitalized adults with mild or moderate COVID-19. The poster presentation will include primary and post-hoc analyses from the Phase 2 clinical trial.

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that data from the company’s SPRINT (SARS-Cov-2 PRotease INhibitor Treatment) study of EDP-235 has been accepted for a poster presentation at ESCMID Global 2024 (formerly ECCMID) being held April 27–30 in Barcelona, Spain.

The poster presentation includes primary and post-hoc analyses from the double-blind, placebo-controlled Phase 2 clinical trial of EDP-235, a 3CL protease inhibitor, in non-hospitalized, symptomatic adults with mild or moderate COVID-19 who were not at high risk for severe disease.

Poster Title: “Efficacy and Safety of EDP-235 in Non-Hospitalized Adults with Mild or Moderate COVID-19: Results from the Phase 2 SPRINT Study”
Abstract Number: 02980
Poster Number: PO423
Day: April 27, 2024
Time: 12:00 p.m. CEST / 6:00 a.m. ET
Session Location: Poster Area
Session Title: COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)
Presenter: Scott T. Rottinghaus, M.D., Chief Medical Officer, Enanta Pharmaceuticals, Inc.

The scientific program for ESCMID Global 2024 can be found at https://www.eccmid.org/scientific-programme

About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s research and development programs are currently focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU) and the company has previously advanced clinical-stage compounds for SARS-CoV-2 (COVID-19) and chronic hepatitis B virus (HBV) infection.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis C virus infection (HCV) and is sold by AbbVie in numerous countries under the trade names MAVYRET^®(U.S.) and MAVIRET^®(ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit http://www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240417219973/en/

Media and Investors Contact

Jennifer Viera

jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.

FAQ

What study data has Enanta Pharmaceuticals announced for presentation at ESCMID Global 2024?

Enanta Pharmaceuticals announced data from the SPRINT study of EDP-235.

What is the focus of the SPRINT study presented at ESCMID Global 2024?

The focus of the SPRINT study is on the efficacy and safety of EDP-235 in non-hospitalized adults with mild or moderate COVID-19.

Who is the presenter of the poster at ESCMID Global 2024?

Scott T. Rottinghaus, M.D., Chief Medical Officer of Enanta Pharmaceuticals, will be the presenter.

When will the poster presentation take place at ESCMID Global 2024?

The poster presentation is scheduled for April 27, 2024, at 12:00 p.m. CEST / 6:00 a.m. ET.

Where will the poster presentation be located at ESCMID Global 2024?

The poster presentation will be in the Poster Area at the session titled COVID-19.

What is the abstract number of the presentation at ESCMID Global 2024?

The abstract number is 02980.

What is the poster number for the presentation at ESCMID Global 2024?

The poster number is PO423.

Where can the scientific program for ESCMID Global 2024 be found?

The scientific program can be found at https://www.eccmid.org/scientific-programme.